🏛️ Verified NIH Record • Updated 2026-05-28

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program (NCT05040373)

Patisiran-LNP Pregnancy Surveillance Program

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Alnylam Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Who can join: Review the eligibility criteria below.

Location: Clinical Trial Site — Iowa City, Iowa

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (7 Sites)

  • Clinical Trial Site — Iowa City, Iowa
  • Clinical Trial Site — Nantes,
  • Clinical Trial Site — Münster,
  • Clinical Trial Site — Pavia,
  • Clinical Trial Site — Groningen,
  • Clinical Trial Site — Lisbon,
  • Clinical Trial Site — Madrid,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Hereditary Transthyretin-mediated (hATTR) Amyloidosis clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗